Theraclone Sciences Announces Identification of New Vulnerable Site on HIV Using Antibodies

Study Published in Immunity in Collaboration with The Scripps Research Institute and IAVI April 25, 2014 Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced the publication of data in the May issue of Immunity regarding antibodies with significant potency and breadth against human immunodeficiency virus (HIV). The study, titled “Broadly neutralizing HIV antibodies define a novel glycan-dependent epitope on the …

Download: Innovative partnerships in HIV vaccine research & development

In November 2012 over 200 delegates participated in the 13th Annual World Vaccine Congress Lyon in France. This event brings together vaccine leaders and policy makers from around the globe. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Hansi J. Dean, Ph.D., Director of New Alliances at International AIDS Vaccine Initiative,entitled: ‘Innovative …

Live event feed: Dr Hanzi Dean

Dr. Dean is Director of New Alliances at the International AIDS Vaccine Initiative (IAVI), where she leads technology identification efforts geared toward addressing unmet needs in a portfolio of international collaborative HIV vaccine research and development projects. Prior to joining IAVI, Dr. Dean was Director of Program Management with PowderJect Vaccines, Inc., managing a portfolio of preclinical and clinical projects …